In re: Suboxone Antitrust Litigation (State of Wisconsin, et al. v. Indivior Inc, et al.)Date Filed: September 22, 2016
District Court: E.D. Pennsylvania – MDL NO. 2445 13-MD-2445 CIV. A. NO. 16-5073
Nature of Suit: Antitrust
Defendant Type: Pharma
Plaintiff Type: State
Court Document: https://www.bloomberglaw.com/document/X15F2DGO0000N?bc=W1siRG9jdW1lbnQiLCIvZG9jdW1lbnQvMT9jaXRhdGlvbj0yMDE3JTIwYmwlMjAzODg1MjImc3VtbWFyeT15ZXMiXV0--eba0a866a924856416b46490b9db849011cd3cd8&jcsearch=2017%2520bl%2520388522#jcite,
In September 2016, 35 state attorneys general and the District of Columbia brought a multi-district case against pharmaceutical manufacturer Indivior, MonoSol RX et al., alleging that the drug companies conspired to delay generic competition for the opioid treatment drug Suboxone, including Sherman Act claims for monopolization, attempted monopolization, and conspiracy to monopolize. The federal district court denied Monosol RX’s motion to dismiss, but granted Indivior’s and Reckitt Benckiser Healthcare’s motion to dismiss claims against them in October 2017. The case is currently in discovery and any motions for class certification is due September 9, 2018.